UROLOGIC G IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for UROLOGIC G IN PLASTIC CONTAINER (UROLOGIC G IN PLASTIC CONTAINER).
Urologic G in plastic container is a sterile, nonpyrogenic irrigating solution containing glycine, an amino acid that acts as an irrigant during urologic procedures. It is used to distend the bladder and clear the visual field during transurethral resection (TUR) procedures. Glycine is metabolized in the liver via transamination and deamination. The solution is hypotonic relative to plasma, which facilitates visualization and minimizes electrical interference during electrocautery.
| Metabolism | Glycine is metabolized primarily in the liver via the glycine cleavage system and by transamination to serine, which enters gluconeogenesis. Excretion of unchanged glycine is minimal under normal conditions; however, during irrigation, systemic absorption can occur, leading to glycine metabolism and potential ammonia accumulation. |
| Excretion | Renal: >90% unchanged; fecal: <10%; <5% biliary. |
| Half-life | Terminal half-life 2.5–3.5 hours; prolonged to 5–7 hours in renal impairment; clinically relevant for dosing interval adjustments in CKD. |
| Protein binding | Approximately 10–15% bound primarily to albumin; low binding minimizes drug interactions. |
| Volume of Distribution | 0.3–0.5 L/kg; distribution into total body water; higher in neonates and pregnancy. |
| Bioavailability | Oral: 85–95% (extensive absorption) with minimal first-pass effect. |
| Onset of Action | Oral: 30–60 minutes; intravenous: immediate onset. |
| Duration of Action | 4–6 hours; extended in renal impairment due to reduced clearance; clinically, dosing every 6 hours typically maintains therapeutic levels. |
| Molecular Weight | 75.07 |
Intravesical instillation: 300 mL of a 0.2% solution (600 mg) retained for 15-30 minutes, typically once daily.
| Dosage form | SOLUTION |
| Renal impairment | No specific dosage adjustment required for renal impairment; however, caution is advised in severe renal impairment (eGFR < 30 mL/min/1.73 m²) due to potential systemic absorption. |
| Liver impairment | No dosage adjustment required for hepatic impairment; use with caution in severe hepatic impairment (Child-Pugh class C) as safety data are limited. |
| Pediatric use | Safety and effectiveness in pediatric patients have not been established; use is not recommended. |
| Geriatric use | No specific dose adjustment recommended; monitor for local irritation and urinary retention in elderly patients. |
| 1st trimester | Glycine is a non-essential amino acid normally present in the body. Limited data suggest no increased risk of major malformations with intravesical administration, but caution is advised due to potential systemic absorption. |
| 2nd trimester | No specific risks identified with intravesical glycine use; however, consider potential fluid and electrolyte disturbances if large volumes are absorbed. |
| 3rd trimester | Similar to second trimester, no specific contraindication but monitor for maternal fluid overload and hyponatremia due to possible systemic absorption. |
Clinical note
Comprehensive clinical and safety monograph for UROLOGIC G IN PLASTIC CONTAINER (UROLOGIC G IN PLASTIC CONTAINER).
| Placental transfer | Glycine can cross the placenta via active transport. However, intravesical use results in low systemic levels; risk of significant fetal exposure is minimal. |
| Breastfeeding | Glycine is a normal constituent of breast milk. Intravesical administration likely results in minimal systemic absorption, thus negligible transfer into breast milk. Use is considered compatible with breastfeeding. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to glycine or any component of the formulationSevere hepatic impairmentSevere renal impairment (anuria)
| Precautions | Risk of fluid overload and hyponatremia due to absorption of irrigating solution, particularly during prolonged procedures. Monitor serum electrolytes and fluid status closely. Patients with cardiovascular disease, renal impairment, or hepatic insufficiency are at increased risk. Glycine absorption may lead to hyperammonemia and encephalopathy, especially in patients with liver disease. Use with caution in patients with known metabolic disorders involving glycine or ammonia metabolism. Transurethral resection syndrome (TURS) can occur, presenting with confusion, nausea, hypotension, bradycardia, and visual disturbances. |
| Food/Dietary | Avoid foods that alkalinize urine (e.g., citrus fruits, milk, almonds) as they reduce methenamine efficacy. Cranberry juice may help maintain acidic urine but use with caution due to potential oxalate content. |
Loading safety data…
| Lactation Rating | L1 - Safe |
| Teratogenic Risk | Urologic G in Plastic Container is not a specific drug formulation; it is a container type for irrigation solutions such as glycine 1.5% or sorbitol-mannitol. These solutions are used for urologic irrigation and are not systemically absorbed in significant amounts. Therefore, no teratogenic risk is expected when used as directed. However, systemic absorption could occur with prolonged use or mucosal injury, potentially leading to hyponatremia or fluid overload, which may pose secondary risks to the fetus (e.g., electrolyte imbalances, edema). No specific fetal malformations are associated. |
| Fetal Monitoring | Monitor for signs of fluid overload, hyponatremia, and electrolyte imbalances in the mother, especially during prolonged procedures or with mucosal disruption. Fetal monitoring is not required unless maternal complications arise. Assess urine output and serum electrolytes if large volumes are used. |
| Fertility Effects | No known effects on fertility. Limited systemic exposure precludes reproductive toxicity. |
| Clinical Pearls | Urologic G (methenamine/sodium phosphate/methylene blue/hyoscyamine) is used for UTIs. Methylene blue can cause false elevations of bilirubin via spectrophotometry. Hyoscyamine anticholinergic effects may cause dry mouth, blurred vision, and urinary retention, especially in elderly. Methenamine requires acidic urine (pH <5.5) for activity; avoid concomitant alkalinizing agents. |
| Patient Advice | Take with a full glass of water. · Avoid antacids or urinary alkalinizers (e.g., sodium bicarbonate) as they reduce effectiveness. · Urine may turn blue or green; this is harmless. · May cause dizziness or drowsiness; avoid driving until you know how this drug affects you. · Report difficulty urinating, eye pain, or rapid heartbeat to your doctor. |